Overcoming Data Quality Challenges During COVID-19 Date Published: May 05, 2020 Whitepaper Signant’s Alan Kott discusses how the COVID-19 pandemic brought unique challenges to clinical trial research, especially in terms of patient safety and data validity. From the perspective of data analytics, the impact of pandemic can be broken into 2 broad categories: operational disruptions and direct impact on patients. Quality data concerns include: Partially or missing data Data tampering or data fabrication Frequent changes in raters or assessment modality Share: LinkedInTweet Recommended Resources 3 Themes and Takeaways From FDA’s Draft Guidance on DCTs Download Now Whitepaper Computerized Adaptive Tests Using PROMIS CAT Download Now Whitepaper The EMA Recommendation Paper on Decentralized Elements in Clinical Trials: An Overview Read Our White Paper Whitepaper